Posts

Posted on

Call of Duty: Black Ops Cold War Available Now Worldwide

Call of Duty: Black Ops Cold War Available Now Worldwide

#1 Selling Call of Duty Series Continues Franchise Momentum and Releases to the Largest, Most Engaged Community at the time of Launch in Call of Duty History

SANTA MONICA, Calif.–(BUSINESS WIRE)–
Activision today announced the worldwide launch of the highly-anticipated Call of Duty®: Black Ops Cold War, an all-new entry in the #1 selling series in Call of Duty and a direct sequel to the fan favorite Call of Duty: Black Ops.

The new title infuses 1980s pop culture into a gripping conspiracy set at the height of the Cold War. In the fictional story campaign players must stop a plot decades in the making that could destabilize the global balance of power and change the course of history. The game delivers the next generation of online multiplayer combat with an arsenal of Cold War weapons and equipment across a wide variety of new maps and modes. Black Ops Cold War also provides an all-new co-operative Zombies survival mode experience.

The title supports cross-play across next generation and current generation systems with cross progression across all modes. Players can look forward to the biggest series of free, post-launch content in Black Ops history across Multiplayer and Zombies, as well as a robust schedule of in-game community events.

“Today’s launch starts the next great Black Ops experience across story, multiplayer and zombies in a direct sequel to one of the most iconic titles in Call of Duty,” said Byron Beede, Executive Vice President and General Manager, Call of Duty, Activision. “This is just the beginning. Our players can look forward to the biggest series of post-launch free content, community events and ongoing support ever in Black Ops plus tight integration across the ecosystem with Warzone. It’s a great time to play Call of Duty.”

The release of a new Black Ops title, the top selling Call of Duty series, adds to the ongoing momentum across Call of Duty following the recent releases of Warzone™ and Modern Warfare®, which, along with Call of Duty: Mobile, have driven Call of Duty to more than 100 million monthly active users. Call of Duty: Mobile has now surpassed more than 300 million downloads* worldwide.

The free-to-play, free-for-everyone Call of Duty: Warzone will take on a new dimension as it integrates with both Black Ops Cold War and Modern Warfare. Player progression will be synchronized across all three titles, and weapon progression from Black Ops Cold War or Modern Warfare both will be shared with Warzone. Starting now, Black Ops Cold War Operators will be available for play in Warzone, and beginning December 10 at the launch of Season One, Black Ops Cold War weapons will become available in Warzone, allowing Warzone players to access either their Black Ops Cold War or Modern Warfare loadouts, respectively, for play.

The battle pass system continues beginning Season One in December with brand new content for Black Ops Cold War and Warzone. Players can progress through the battle pass system by playing any of the three Call of Duty games.

Call of Duty: Black Ops Cold War is available now worldwide on PlayStation® 5 (Australia, Japan, New Zealand, North America, Singapore, South Korea; rest of world availability Nov. 19th), PlayStation® 4, the Xbox Series X|S and Xbox One, and on PC, in a fully optimized experience for Battle.net, Blizzard Entertainment’s online gaming service. The title is published by Activision, a wholly-owned subsidiary of Activision Blizzard (NASDAQ: ATVI), and developed by award-winning studios Treyarch and Raven Software with additional development support from Beenox, Demonware, High Moon Studios, Activision Shanghai and Sledgehammer Games. For more information visit: www.callofduty.com, or follow @CallofDuty on Twitter, Instagram and Facebook.

About Activision

Headquartered in Santa Monica, California, Activision is a leading global producer and publisher of interactive entertainment. Activision maintains operations throughout the world and is a division of Activision Blizzard (NASDAQ: ATVI), an S&P 500 company. More information about Activision and its products can be found on the company’s website, www.activision.com or by following @Activision.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves Activision Publishing’s expectations, plans, intentions or strategies regarding the future, including statements about the expected availability, features, and content for Call of Duty: Black Ops Cold War and Warzone, including about Season One, the battle pass system and community events, are forward-looking statements that are not facts and involve a number of risks and uncertainties. Factors that could cause Activision Publishing’s actual future results to differ materially from those expressed in the forward-looking statements set forth in this release include unanticipated product delays and other factors identified in the risk factors sections of Activision Blizzard’s most recent annual report on Form 10K and any subsequent quarterly reports on Form 10-Q. The forward-looking statements in this release are based upon information available to Activision Publishing and Activision Blizzard as of the date of this release, and neither Activision Publishing nor Activision Blizzard assumes any obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Activision Publishing or Activision Blizzard and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

*Based on Activision internal estimates

ACTIVISION, CALL OF DUTY, CALL OF DUTY BLACK OPS, CALL OF DUTY WARZONE, MODERN WARFARE, and WARZONE are trademarks of Activision Publishing, Inc. All other trademarks and trade names are the properties of their respective owners.

“PlayStation” is a registered trademark and “PS4” is a trademark of Sony Computer Entertainment Inc.

PR Contact:

Activision

Kyle Walker

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Technology Electronic Games Teens Women Entertainment Men Software Audio/Video Consumer Consumer Electronics

MEDIA:

Posted on

Akero Presents Additional Positive Data from Phase 2a BALANCED Study Demonstrating Potential of Efruxifermin as a Foundational NASH Monotherapy

Akero Presents Additional Positive Data from Phase 2a BALANCED Study Demonstrating Potential of Efruxifermin as a Foundational NASH Monotherapy

Data to be presented at the Presidential Plenary Talk at The Liver Meeting®

100% of patients in 50mg group demonstrated more than 50% relative reduction in liver fat

50% of patients with F2/F3 fibrosis at baseline achieved two stage improvement in fibrosis score

Type 2 diabetic patients showed improved glycemic control with HbA1c reduced by up to 0.9%

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–
Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced the presentation of additional data analysis from the Phase 2a BALANCED study at the Presidential Oral Plenary Session at The Liver Meeting®. The data continue to demonstrate the potential of efruxifermin (EFX) as a foundational monotherapy for patients with non-alcoholic steatohepatitis (NASH).

Overall, the data show large magnitudes of reduction in liver fat across all EFX dose groups with 100% of participants in the 50mg EFX dose group achieving more than 50% relative reduction in liver fat and 53% of patients in the same dose group achieving more than 70% relative reduction in liver fat.

Among all EFX-treated patients who were fibrosis stage F2 or F3 at baseline (n=22), 50% experienced a two-stage improvement in fibrosis (n=11), while 68% experienced at least a one-stage improvement in fibrosis (n=15).

Additional analysis of the BALANCED data showed substantial improvement in glycemic control for patients with both NASH and Type 2 diabetes, a group that comprises about half of all NASH patients. The company previously reported mean absolute reductions in HbA1c among all study participants of 0.1% for the 28mg dose, 0.4% (p<0.05) for the 50mg dose and 0.5% (p<0.01) for the 70mg dose. In patients with both NASH and Type 2 diabetes, researchers observed decreases of 0.6% in the 50mg dose and 0.9% (p<0.01) in the 70mg dose. Among EFX patients with NASH and Type 2 diabetes, the relative decreases in mean C-peptide levels ranged from 27 to 33% across EFX dose groups, compared to 22 to 29% for all EFX patients.

“Additional analyses from the BALANCED study, including the proportion of subjects with at least 50 and 70% reductions in liver fat and the high proportion of subjects with F2/F3 fibrosis at baseline with fibrosis improvement, strengthens the potential of EFX to be truly transformative for people living with NASH, with improvements across multiple parameters for NASH and cardio-metabolic conditions,” said Andrew Cheng, M.D., Ph.D., president and CEO of Akero. “With some of the strongest results reported to date in NASH, we eagerly anticipate the initiation of our adaptive Phase 2b/3 study of efruxifermin with hopes of improving lives of the more than 17 million Americans who are living with this disease.”

EFX has received European Medicines Agency Priority Medicines (PRIME) designation as a treatment for NASH. Akero plans to begin a Phase 2b/3 adaptive clinical trial in biopsy confirmed NASH patients in the first half of 2021. The company will be using 28mg and 50mg doses for that trial.

Akero previously reported data from the BALANCED study demonstrating that each of the 28, 50 and 70mg EFX dose groups met the primary endpoint compared to placebo, with absolute reductions of 12%, 13% and 14% of liver fat, respectively, compared with 0.3% for placebo, and relative reductions of 63%, 71% and 72% percent, compared to 0% for placebo. All of these results were highly statistically significant at p<0.001.

Prior Reporting of secondary and exploratory endpoints revealed that of the 40 EFX treatment responders who had end-of-treatment biopsies, 48% achieved at least a one-stage improvement in fibrosis without worsening of NAFLD activity score (NAS) and 28% achieved at least a two-stage improvement in fibrosis. Additionally, 48% of responders achieved NASH resolution with no worsening of fibrosis. Improvements in glycemic control and dyslipidemia, as well as weight loss, were also observed across all dose groups. Treatment with EFX was generally reported to be well tolerated.

About NASH

NASH (non-alcoholic steatohepatitis) is a serious form of NAFLD (non-alcoholic fatty liver disease) and is estimated to affect 17 million Americans. NASH is closely linked to the obesity and diabetes epidemics seen around the world. NASH is characterized by an excessive accumulation of fat in the liver that causes stress and injury to liver cells, leading to inflammation and fibrosis, which can progress to cirrhosis, liver failure, cancer and eventually death. NASH is a leading cause of liver transplants in the US and Europe.

About the BALANCED Study

The Phase 2a BALANCED study is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial in biopsy-confirmed adult patients with NASH. The main study enrolled a total of 80 patients. Participants were randomized to receive weekly subcutaneous doses of efruxifermin (EFX), formerly known as AKR-001, or placebo for up to 16 weeks, with safety and tolerability followed through week 20. The primary efficacy endpoint for the study is absolute change from baseline in hepatic fat fraction measured by magnetic resonance imaging – proton density fat fraction (MRI-PDFF) at week 12. Secondary measures include change from baseline in ALT at 12 weeks, the number of patients who had a decrease of ≥2 points in the NAFLD activity score (NAS) at 24 weeks and safety and tolerability measures.

About Efruxifermin

Efruxifermin (EFX), formerly known as AKR-001, is Akero’s lead product candidate for NASH, currently being evaluated in the ongoing Phase 2a BALANCED study. EFX is designed to reduce liver fat and inflammation, reverse fibrosis, increase insulin sensitivity and improve lipoproteins. This holistic approach offers the potential to address the complex, multi-system disease state of NASH, including improvements in lipoprotein risk factors linked to cardiovascular disease – the leading cause of death in NASH patients. Engineered to mimic the biological activity profile of native FGF21, EFX offers convenient once-weekly dosing and has been generally well-tolerated in clinical trials to date.

About Akero Therapeutics

Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance to improve overall health. The company’s lead product candidate, Efruxifermin (EFX), formerly known as AKR-001, is currently being evaluated in an ongoing Phase 2a clinical trial. Akero Therapeutics is headquartered in South San Francisco, CA. For more information, please visit www.akerotx.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Akero’s guidance regarding its business plans and objectives for EFX, including the therapeutic potential and clinical benefits thereof, as well as the safety and tolerability of EFX and future clinical development plans; Akero’s Phase 2a BALANCED clinical trial, including its results and Akero’s analysis of such results; Akero’s design, implementation and expected timing of the Phase 2b/3 trial; the potential benefits conferred by the EMA on Akero’s PRIME designation; and the potential impact of COVID-19 on patient retention, strategy, future operations and clinical trials.

Any forward-looking statements in this statement are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the impact of public health epidemics affecting countries or regions in which we have operations or do business, such as COVID-19, including potential negative impacts on Akero’s employees, manufacturers, supply chain and production as well as on global economies and financial markets; the company’s ability to execute on its strategy; positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States; and risks related to the competitive landscape. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Akero’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in the company’s 2019 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) and quarterly reports on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Akero’s other filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Akero undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:

Carolyn Hawley

Canale Communications

[email protected]

619-849-5382

Investor Contact:

Christina Tartaglia

Stern Investor Relations

[email protected]

212-362-1200

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Health Diabetes Research Pharmaceutical Science Biotechnology

MEDIA:

Logo
Logo
Posted on

Emerald Appoints Hervé Sedky as President and Chief Executive Officer

Emerald Appoints Hervé Sedky as President and Chief Executive Officer

Sedky Brings a Distinguished Track Record in Events and Business Travel

NEW YORK–(BUSINESS WIRE)–
Emerald Holding, Inc. (NYSE:EEX) (“Emerald” or the “Company”) today announced that the Company’s Board of Directors has appointed Hervé Sedky to the position of President and Chief Executive Officer of Emerald. Mr. Sedky will assume his new role on January 5, 2021. Brian Field, Emerald’s Interim President and Chief Executive Officer, will continue to serve as the Company’s Chief Operating Officer.

“We are thrilled to have Hervé join the Emerald team. His long and successful career in leadership roles serving the business travel and events markets, along with his strategic acumen, transformative approach, and results-orientation are an ideal fit for Emerald’s next phase of growth,” said Kosty Gilis, Chairman of Emerald’s Board of Directors.

Mr. Sedky brings three decades of experience including, most recently, six years as President of Reed Exhibitions Americas, where he led a business of over 100 annual sector-leading events in North and South America. This highly-relevant role is complemented by a distinguished 20-year executive career at the American Express Company, where he held the title of Senior Vice President and General Manager of American Express Business Travel, guiding the growth of a $1 billion revenue business and serving on American Express’ senior management team.

“I am excited to join the world-class Emerald team and can’t think of a better place to reinforce what people and businesses need most: human connections. If there is one thing we have learned personally and professionally from the ongoing pandemic, it is that nothing can replace the high value of the live, in-person experience. Emerald has already begun to demonstrate that face-to-face events can once again be staged safely. We will continue to enhance our customer experience with the extraordinary learning we have acquired this year and apply the kind of creativity we didn’t think possible—the kind of innovation that will drive better results, better customer experience and value,” said Mr. Sedky.

“Hervé is a tremendous leader whom I have known as an industry colleague for some time; he demonstrates a fantastic blend of personal leadership, industry insight, and a keen customer focus. I am excited to work closely with him, as we together continue to accelerate Emerald’s pathways for growth, and build upon the many remarkable foundations we have put in place over this year,” said Mr. Field.

Mr. Gilis added, “On behalf of the entire Board, I would like to sincerely thank Brian for assuming the role of Interim President and CEO for the last year. He has very capably led the organization during what has been an unexpectedly turbulent time for the industry against the backdrop of the coronavirus pandemic, all while driving forward many important transformational initiatives for the business which have positioned Emerald to emerge stronger on the other side of the pandemic. The Board looks forward to continuing to work with Brian in his capacity as Chief Operating Officer.”

About Emerald

Emerald is a leader in building dynamic, market-driven business-to-business platforms that integrate live events with a broad array of industry insights, digital tools, and data-focused solutions to create uniquely rich experiences. As true partners, we at Emerald strive to build our customers’ businesses by creating opportunities that inspire, amaze, and deliver breakthrough results. With over 140 events each year, our teams are creators and connectors who are thoroughly immersed in the industries we serve and committed to supporting the communities in which we operate.

Emerald Holding, Inc.

David Doft

Chief Financial Officer

1-866-339-4688 (866EEXINVT)

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Software Technology Networks Data Management

MEDIA:

Posted on

Ondas Holdings Inc. Announces Reverse Stock Split of Common Stock

Ondas Holdings Inc. Announces Reverse Stock Split of Common Stock

SUNNYVALE, Calif.–(BUSINESS WIRE)–
Ondas Holdings Inc. (OTCQB: ONDS), through its wholly owned subsidiary, Ondas Networks Inc., a developer of private licensed wireless data networks for mission-critical industrial markets (the “Company”), today announced it will effect a one-for-three reverse stock split of its issued and outstanding Common Stock. Pursuant to the Certificate of Change filed with the Secretary of State of the State of Nevada, the reverse stock split will be effective at 5:31 p.m., Eastern Time, on November 13, 2020. The Company expects that upon the opening of trading on November 16, 2020, its Common Stock will trade on the OTCQB on a split-adjusted basis under the current trading symbol “ONDS” and the new CUSIP number 68236H 204.

No fractional shares will be issued as a result of the reverse stock split. Any fractional shares that would result from the reverse stock split will be rounded up to the nearest whole share. Following the reverse stock split, the Company will have 116,666,667 shares of Common Stock authorized and approximately 19,796,029 shares of Common Stock outstanding.

Shareholders of record are not required to send in their current stock certificates or evidence of book-entry or other electronic positions for exchange. Following the effectiveness of the reverse stock split, each stock certificate and book-entry or other electronic position representing issued and outstanding shares of the Company’s common stock will be automatically adjusted. Those shareholders holding common stock in “street name” will receive instructions from their brokers if they need to take any action in connection with the reverse stock split.

About Ondas Holdings Inc.

Ondas Holdings Inc., through its wholly owned subsidiary, Ondas Networks Inc., is a developer of private licensed wireless data networks for mission-critical industrial markets. The Company designs and manufactures its multi-patented, Software Defined Radio (SDR) platform for Mission Critical IoT (MC- IoT) applications. Ondas Networks’ customer end markets include utilities, oil and gas, transportation, and government entities whose demands span a wide range of mission critical applications that require secure communications over large and diverse geographical areas, many of which are within challenging radio frequency environments. Customers use the Company’s SDR technology to deploy their own private licensed broadband wireless networks. The Company also offers mission-critical entities the option of a managed network service. Ondas Networks’ SDR technology supports IEEE 802.16s, the new worldwide standard for private licensed wide area industrial networks. For additional information, visit www.ondas.com, www.otcmarkets.com or follow Ondas Networks on Twitter and LinkedIn.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We caution readers that forward-looking statements are predictions based on our current expectations about future events.

These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance, or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, the risks discussed under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 13, 2020, and in our other filings with the SEC. We undertake no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as required by law.

Stewart Kantor, CFO

Ondas Holdings Inc.

888.350.9994 Ext. 1009

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Technology Networks Data Management

MEDIA:

Logo
Logo
Posted on

KB Home Announces the Grand Opening of Central Park – Villa Collection

KB Home Announces the Grand Opening of Central Park – Villa Collection

Homebuilder offers personalized, new paired homes in a premier Denver master-planned community priced from the $450,000s

DENVER–(BUSINESS WIRE)–
KB Home (NYSE: KBH) today announced the grand opening of its Central Park – Villa Collection, a new enclave of paired homes situated in the final phase of Central Park, one of Denver’s most popular master-planned communities. The newly developed North End will serve as the final chapter for this highly desirable neighborhood. Homebuyers will enjoy the community’s proximity to Interstate 70, Denver International Airport and the area’s major job centers. Additionally, the new community hosts 80 acres of amenities, including pools, athletic fields, sports courts, jogging and biking paths, barbecue and picnic areas, a play fountain and a large playground with climbing boulders as well as a sledding hill, remote control boating lake and amphitheater.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201113005131/en/

KB Home announces the grand opening of Central Park – Villa Collection. (Photo: Business Wire)

KB Home announces the grand opening of Central Park – Villa Collection. (Photo: Business Wire)

The low-maintenance, two-story, paired homes at KB Home’s Central Park – Villa Collection showcase desirable design characteristics like gourmet kitchens overlooking expansive great rooms, lofts, large master suites with walk-in closets, and optional basements. The community’s floor plans feature up to five bedrooms and three-and-a-half baths, and range in size from approximately 1,200 to 1,500 square feet. The community also offers the KB Home Office, a dedicated room that homebuyers can personalize for the way they work.

“We are excited to offer our popular Villa Collection at one of Denver’s premier master-planned communities. In addition to featuring world-class amenities, Central Park is also close to a variety of shopping, dining and entertainment as well as Denver International Airport and the area’s major employment centers,” said Randy Carpenter, President of KB Home’s Colorado division. “As with other KB Home communities, Central Park – Villa Collection provides home shoppers the opportunity to purchase a new KB home that can be personalized to reflect their lifestyle and needs.”

KB Home stands out from other homebuilders as the company gives homebuyers exceptional choice and control. KB Home starts by offering a wide variety of homes at an affordable price. From there, the builder gives buyers the ability to personalize their homes from homesites and floor plans to design features. The KB Home team works hand in hand with homeowners every step of the way so they have a real partner in the process.

Every KB home is designed to be ENERGY STAR® certified thanks to the quality construction techniques and materials utilized that ultimately deliver significant savings on utility bills compared to used homes. Additionally, all new KB homes are designed to deliver an enhanced indoor environment and include high performance ventilation systems, low- or zero-VOC products and other features guided by the Environmental Protection Agency’s (EPA) Indoor airPLUS standards.

The Central Park – Villa Collection sales office and model homes are open for private in-person tours by appointment, and walk-in visits are welcome. Homebuyers also have the flexibility to arrange a live video tour with a sales counselor. Pricing begins from the $450,000s.

For more information on KB Home, call 888-KB-HOMES or visit kbhome.com.

About KB Home

KB Home is one of the largest and most recognized homebuilders in the United States and has been building quality homes for over 60 years. Today, KB Home operates in 42 markets across eight states, serving a wide array of buyer groups. What sets us apart is how we give our customers the ability to personalize their homes from homesites and floor plans to cabinets and countertops, at a price that fits their budget. We are the first builder to make every home we build ENERGY STAR® certified. In fact, we go beyond the EPA requirements by ensuring every ENERGY STAR certified KB home has been tested and verified by a third-party inspector to meet the EPA’s strict certification standards, which help to lower the cost of ownership and to make our new homes healthier and more comfortable than new ones without certification. We also work with our customers every step of the way, building strong personal relationships so they have a real partner in the homebuying process, and the experience is as simple and easy as possible. Learn more about how we build homes built on relationships by visiting kbhome.com.

Craig LeMessurier, KB Home

925-580-1583

[email protected]

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Architecture Construction & Property Environment Family Urban Planning Consumer Interior Design Residential Building & Real Estate

MEDIA:

Logo
Logo
Photo
Photo
KB Home announces the grand opening of Central Park – Villa Collection. (Photo: Business Wire)
Posted on

VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at The Liver Meeting® 2020

VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at The Liver Meeting® 2020

CAMBRIDGE, Mass.–(BUSINESS WIRE)–
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the presentation of its abstract featuring data from one of the pivotal Phase 3 studies (PROTECT) evaluating Sci-B-Vac®, the company’s 3-antigen prophylactic hepatitis B (HBV) vaccine, in an e-poster presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting®, which took place on November 13, 2020.

Poster #: 0742

Title:A 3-antigen hepatitis B vaccine (3AV) provides consistently higher seroprotection rates (SPR) and anti-HBs titers compared to single-antigen vaccine in adults with comorbidities known to be associated with poor response to vaccinations: Results from the phase 3 double-blind, randomized study (PROTECT)

Joanne Langley, M.D., Professor of Pediatrics and Community Health and Epidemiology, CIHR-GSK Chair in Pediatric Vaccinology, Dalhousie University, and Head of the Division of Infectious Disease, IWK Health Centre, and principal investigator of the PROTECT study delivered the poster presentation.

“In the PROTECT study, the overall immunogenicity of Sci-B-Vac was higher than that of Engerix-B in all study participants; this is demonstrated across key subgroup populations where Sci-B-Vac induced consistently higher seroprotection rates and higher mean concentrations of hepatitis B surface antibodies,” said Dr. Langley. “These subgroup data are significant, as there is an unmet medical need in certain populations, including adults over the age of 45 and those with underlying comorbidities, who have known reduced immune responses to single-antigen hepatitis B vaccines.”

The poster highlighted Sci-B-Vac’s ability to induce higher peak (Day 196) seroprotection rates (SPRs) and serum levels of HBV surface antibodies (anti-HBs titers) compared to Engerix-B, persistence and durability of which are believed to be dependent upon peak levels induced. The data included:

  • Consistently higher SPRs induced in all subjects vaccinated with Sci-B-Vac compared to Engerix-B:
    • In all subjects, age 18+ : 91.4% vs. 76.5% (difference: 14.9%)

      • Adults 18-44 years : 99.2% vs. 91.1% (difference: 8.1%)
      • Adults 45-64 years : 94.8% vs. 80.1% (difference: 14.7%)
      • Adults 65+ : 83.6% vs. 64.7% (difference: 18.9%)
    • These results were consistent across notable subgroups, including diabetics (83.3% vs. 58.3%) and obese individuals (89.2% vs. 68.1%)
    • SPR is defined as the percent (%) of subjects who achieve anti-HBs titers ≥ 10 mIU/mL
  • Sci-B-Vac elicited higher geometric mean concentration (GMC) of anti-HBs titers in all subjects compared to Engerix-B:
    • 6x higher GMC of anti-HBs titers in all adults age 18+ (1148.2 mIU/mL vs. 192.6 mIU/mL)
    • 4-8x higher antibody GMCs were elicited in study subjects with Sci-B-Vac compared to Engerix-B regardless of age (65+ : 410.2 mIU/mL vs. 63.7 mIU/mL), obesity (884.0 mIU/mL vs. 110.0 mIU/mL), or diabetic status (222.3 mIU/mL vs. 41.3 mIU/mL)

A copy of the e-poster is available on the “Events/Presentations” page in the “Investors” section of VBI’s website.

About VBI Vaccines Inc.

VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with: (1) the only 3-antigen hepatitis B vaccine, Sci-B-Vac®, which is approved for use and commercially available in Israel and recently completed its Phase 3 program in the U.S., Europe, and Canada; and (2) an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI’s enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI’s lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic coronavirus vaccine program. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

Website Home: http://www.vbivaccines.com/

News and Insights: http://www.vbivaccines.com/wire/

Investors: http://www.vbivaccines.com/investors/

Cautionary Statement on Forward-looking Information

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). The Company cautions that such statements involve risks and uncertainties that may materially affect the Company’s results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the impact of general economic, industry or political conditions in the United States or internationally; the impact of the ongoing COVID-19 pandemic on our clinical studies, manufacturing, business plan, and the global economy; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company’s products. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company’s filings with the SEC and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the SEC on March 5, 2020, and filed with the Canadian security authorities at sedar.com on March 5, 2020, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law.

VBI Contact

Nicole Anderson

Director, Corporate Communications & IR

Phone: (617) 830-3031 x124

Email: [email protected]

KEYWORDS: United States North America Canada Massachusetts

INDUSTRY KEYWORDS: Research Infectious Diseases FDA Clinical Trials Other Health Biotechnology Pharmaceutical Health Science Oncology

MEDIA:

Logo
Logo
Posted on

Carvana Rallies Consumers to Live Feelessly™

Carvana Rallies Consumers to Live Feelessly™

Carvana is Changing the Way People Buy Cars and Changing the Way People Look at Hidden Fees

PHOENIX–(BUSINESS WIRE)–
Leading online auto retailer Carvana (NYSE: CVNA), known for its easy, transparent car buying experience, is encouraging consumers to take a stand against hidden, last-minute fees; to Live Feelessly™ and seek pricing transparency when making purchases. Carvana’s Live Feelessly™ campaign features a new 30-second TV ad, digital assets and social media movement, #FeelessFriday, rallying consumers to go fee-free on Fridays.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201113005200/en/

Carvana is rallying consumers to Live Feelessly™ and take a stand against hidden, last-minute fees. (Photo: Business Wire)

Carvana is rallying consumers to Live Feelessly™ and take a stand against hidden, last-minute fees. (Photo: Business Wire)

“When we pioneered online car buying more than seven years ago, we knew we would do a lot of things differently, including not relying on standard industry practices like last-minute ‘doc fees,’” said Carvana Chief Brand Officer Ryan Keeton. “At Carvana, we believe in treating people better, and empowering them to make their next purchase on their own terms. That means giving our customers detailed, 360-degree photos of every vehicle, inside and out, financing terms in minutes, a real offer on their trade-in and no hidden, last-minute fees; a transparent purchase from start to finish so they can Live Feelessly™.”

Consumers’ lives are filled with fees, from food delivery, to travel, to car buying, but when you Live Feelessly™ you choose freedom over fees. Starting today, social media fans can show how they are going to Live Feelessly™ by making Fridays fee-free and posting their #FeelessFriday actions and tips on Instagram and Twitter. Whether it’s cooking dinner instead of ordering delivery, going camping instead of paying resort fees at a hotel or getting cash at your bank instead of paying ATM fees, tag @gocarvana on Instagram or @carvana on Twitter and show off your #FeelessFriday.

Carvana allows customers to shop more than 20,000 vehicles online, finance, purchase and schedule touchless home delivery or Car Vending Machine pickup in as little as 5 minutes from the comfort of home or on the go via mobile device. “Doc fees,” or documentation fees, are additional costs at the discretion of the dealership and Carvana never charges them.

About Carvana (NYSE: CVNA)

Founded in 2012 and based in Phoenix, Carvana’s (NYSE: CVNA) mission is to change the way people buy cars. By removing the traditional dealership infrastructure and replacing it with technology and exceptional customer service, Carvana offers consumers an intuitive and convenient online car buying and financing platform. Carvana.com enables consumers to quickly and easily shop more than 20,000 vehicles, finance, trade-in or sell their current vehicle to Carvana, sign contracts, and schedule as-soon-as-next-day delivery or pickup at one of Carvana’s proprietary automated Car Vending Machines.

For further information on Carvana, please visit www.carvana.com, or connect with us on Facebook, Instagram or Twitter.

Carvana

Amy O’Hara

[email protected]

KEYWORDS: United States North America Arizona

INDUSTRY KEYWORDS: Online Retail Advertising Retail Communications Automotive Social Media General Automotive

MEDIA:

Logo
Logo
Photo
Photo
Carvana is rallying consumers to Live Feelessly™ and take a stand against hidden, last-minute fees. (Photo: Business Wire)
Posted on

Chemtrade Appoints Douglas Muzyka to Board of Trustees;

Chemtrade Appoints Douglas Muzyka to Board of Trustees;

Amends Declaration of Trust

TORONTO–(BUSINESS WIRE)–
Chemtrade Logistics Income Fund (TSX:CHE.UN) announced today that it amended and restated its Declaration of Trust to enable a minority of Board members to be non-resident Canadians, to permit virtual Board and unitholder meetings, to facilitate electronic signatures and delivery, to clarify annual meeting procedures and to make minor administrative amendments. The adoption of this amended and restated Declaration of Trust will be voted upon at the next unitholder meeting. Chemtrade also announced that Douglas Muzyka has been appointed as a member of the Board of Trustees. Mr. Muzyka had been attending meetings of the Board and its Committees in an advisory capacity since January 1, 2018 due to the residency restrictions. All Board members’ terms expire at the next annual unitholder meeting.

Mr. Muzyka has extensive experience in the chemical industry. He retired from E.I. DuPont de Nemours (DuPont), an international manufacturer of chemical products, specialty materials, consumer and industrial products. As Senior Vice President and Chief Science and Technology Officer, he led a science and engineering organization of over 10,000 scientists and engineers. He previously served as President of DuPont, Greater China and DuPont China Holding Co. Ltd., Vice President and General Manager of DuPont Nutrition and Health, President and CEO of DuPont Canada, Inc., President and General Manager of DuPont Mexico and as a research scientist.

About Chemtrade

Chemtrade operates a diversified business providing industrial chemicals and services to customers in North America and around the world. Chemtrade is one of North America’s largest suppliers of sulphuric acid, spent acid processing services, inorganic coagulants for water treatment, sodium chlorate, sodium nitrite, sodium hydrosulphite, and phosphorus pentasulphide. Chemtrade is a leading regional supplier of sulphur, chlor-alkali products, liquid sulphur dioxide, potassium chloride, and zinc oxide. Additionally, Chemtrade provides industrial services such as processing by-products and waste streams.

Mark Davis

President & CEO

Tel: (416) 496-4176

Rohit Bhardwaj

Vice President, Finance & CFO

Tel: (416) 496-4177

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Chemicals/Plastics Manufacturing

MEDIA:

Logo
Logo
Posted on

KB Home Announces the Grand Opening of Central Park – Starlight Collection

KB Home Announces the Grand Opening of Central Park – Starlight Collection

Homebuilder offers personalized, new mid-century modern homes in a premier Denver master-planned community

DENVER–(BUSINESS WIRE)–
KB Home (NYSE: KBH) today announced that it will debut its stunning Starlight Collection in the final phase of the premier Central Park master plan. The unique ranch-style homes evoke a mid-century modern aesthetic, with architectural design elements that are relatively rare in today’s new-home market. Central Park is one of Denver’s most popular master-planned communities, and the newly developed North End will serve as the final chapter for this highly desirable neighborhood. Homebuyers will enjoy the community’s proximity to Interstate 70, Denver International Airport and the area’s major job centers. Additionally, the new community hosts 80 acres of amenities, including pools, athletic fields, sports courts, jogging and biking paths, barbeque and picnic areas, a play fountain and a large playground with climbing boulders as well as a sledding hill, remote control boating lake and amphitheater.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201113005143/en/

KB Home announces the grand opening of Central Park – Starlight Collection. (Photo: Business Wire)

KB Home announces the grand opening of Central Park – Starlight Collection. (Photo: Business Wire)

KB Home has put its own spin on the architectural designs of the 1950s, as the new homes at Central Park – Starlight Collection exhibit many of the period’s classic features, including clean lines and expansive great rooms as well as large-pane windows and sliding glass doors that promote indoor-outdoor living. The community’s one-story floor plans feature up to four bedrooms and three-and-a-half baths, and range in size from approximately 2,300 to 2,800 square feet. The home’s large footprints also allow for expansive basements, which can be finished to provide up to an additional 1,800 square feet, enough space for a bedroom, full bath, home office and large recreation room.

“Integrating natural surroundings was a focus of mid-century architecture, which features rooms with multiple outdoor views or access points and encourages an appreciation for indoor/outdoor living. Our new homes provide a continuous flow from the kitchen to the great room and outdoors, creating a grand living space for homeowners to enjoy nature and host family gatherings,” said Randy Carpenter, President of KB Home’s Colorado division. “We are excited to offer our popular Starlight Collection at one of Denver’s premier master-planned communities. In addition to featuring world-class amenities, Central Park is also close to a variety of shopping, dining and entertainment as well as Denver’s major employment centers.”

KB Home stands out from other homebuilders as the company gives homebuyers exceptional choice and control. KB Home starts by offering a wide variety of homes at an affordable price. From there, the builder gives buyers the ability to personalize their homes from homesites and floor plans to design features. The KB Home team works hand in hand with homeowners every step of the way so they have a real partner in the process.

Every KB home is designed to be ENERGY STAR® certified thanks to the quality construction techniques and materials utilized that ultimately deliver significant savings on utility bills compared to used homes. Additionally, all new KB homes are designed to deliver an enhanced indoor environment and include high performance ventilation systems, low- or zero-VOC products and other features guided by the Environmental Protection Agency’s (EPA) Indoor airPLUS standards.

The Central Park – Starlight Collection sales office and model home are open for private in-person tours by appointment, and walk-in visits are welcome. Homebuyers also have the flexibility to arrange a live video tour with a sales counselor. Pricing begins from the $740,000s.

For more information on KB Home, call 888-KB-HOMES or visit kbhome.com.

About KB Home

KB Home is one of the largest and most recognized homebuilders in the United States and has been building quality homes for over 60 years. Today, KB Home operates in 42 markets across eight states, serving a wide array of buyer groups. What sets us apart is how we give our customers the ability to personalize their homes from homesites and floor plans to cabinets and countertops, at a price that fits their budget. We are the first builder to make every home we build ENERGY STAR® certified. In fact, we go beyond the EPA requirements by ensuring every ENERGY STAR certified KB home has been tested and verified by a third-party inspector to meet the EPA’s strict certification standards, which help to lower the cost of ownership and to make our new homes healthier and more comfortable than new ones without certification. We also work with our customers every step of the way, building strong personal relationships so they have a real partner in the homebuying process, and the experience is as simple and easy as possible. Learn more about how we build homes built on relationships by visiting kbhome.com.

Craig LeMessurier, KB Home

925-580-1583

[email protected]

KEYWORDS: United States North America Colorado

INDUSTRY KEYWORDS: Residential Building & Real Estate Architecture Construction & Property Interior Design

MEDIA:

Logo
Logo
Photo
Photo
KB Home announces the grand opening of Central Park – Starlight Collection. (Photo: Business Wire)
Posted on

NCR to Host Virtual Investor Day

NCR to Host Virtual Investor Day

ATLANTA–(BUSINESS WIRE)–
NCR Corporation (NYSE: NCR), a global enterprise technology provider for the banking, retail and hospitality industries, today announced it will host a virtual Investor Day 2020 event on Dec. 3, 2020 at 9:30 a.m. – 12:00 p.m. Eastern Time.

NCR executives presenting during the event include President & Chief Executive Officer Mike Hayford, Chief Operating Officer Owen Sullivan, Chief Financial Officer Tim Oliver and other senior leaders.

Event attendees will learn about:

  • NCR’s strategy to be a software- and services-led technology partner of choice to run the store, restaurant and self-service banking;
  • How NCR is shifting to recurring revenue and driving margin expansion; and
  • Why NCR is a compelling investment and well positioned for growth.

Investors are invited to register here by Nov. 30.

A live webcast and replay of the event will be available in the Investor Relations section of NCR.com (investor.ncr.com) for 90 days following the event.

About NCR Corporation

NCR Corporation (NYSE: NCR) is a leading software- and services-led enterprise provider in the financial, retail and hospitality industries. NCR is headquartered in Atlanta, Ga., with 36,000 employees and does business in 180 countries. NCR is a trademark of NCR Corporation in the United States and other countries.

Web site: www.ncr.com

Twitter: @NCRCorporation

Facebook: www.facebook.com/ncrcorp

LinkedIn: www.linkedin.com/company/ncr-corporation

YouTube: www.youtube.com/user/ncrcorporation

Investor Contact

Michael Nelson

NCR Corporation

678-808-6995

[email protected]

Media Contact

Scott Sykes

NCR Corporation

212-589-8428

[email protected]

KEYWORDS: Georgia United States North America

INDUSTRY KEYWORDS: Software Restaurant/Bar Other Retail Finance Banking Professional Services Technology Retail

MEDIA:

Logo
Logo